in the efficacy analysis , the event rate per year for stroke , myocardial infarction or vascular death , considered together , was 15.3 % in the placebo group and 10.8 % in the ticlopidine group , representing a relative risk reduction with ticlopidine of 30.2 % ( 95 % confidence interval 7.5-48.3 % ; p = 0.006 ) .
C0038454
stroke
C0040207
ticlopidine